The Independent Vet Defense Finally Has Numbers

For roughly a decade, the vet consolidation story has run one direction. Covetrus just gave the independent half of the market its first set of real counter-data. The VetSuite buying-and-services program crossed 4,000 member practices on May 21, with disclosed program economics that prior milestone releases held back: $150 million in cumulative member benefits, $30,000 in average annual savings per practice, and 27% more online pharmacy revenue per DVM than non-participating independents. Those are the metrics an independent owner fielding a corporate acquisition offer can finally bring to the table.

Covetrus VetSuite crosses 4,000 member practices, discloses $150M in cumulative benefits

Covetrus announced on May 21, 2026 that VetSuite, its dedicated program for independent veterinary clinics, has surpassed 4,000 member practices nationwide. The release marks the first time the company has published practice-level program economics alongside the membership-count milestone.

The disclosed numbers, per Covetrus: $150 million in cumulative member benefits since the program’s launch; an average of $30,000 in annual savings per practice through rebates, preferred supplier deals, price list discounts, and additional support; and 27% higher online pharmacy revenue per DVM in 2026 versus non-participating independent clinics. Members have realized more than $60 million in rebates alone to date.

VetSuite is positioned as Covetrus’s defensive answer to the corporate consolidation pressure on independent practices. It bundles group purchasing, the Covetrus Platform, and services into a program designed to give an independent clinic the buying power and operational tools of a corporate-network hospital while keeping it independent.

For comparison, Covetrus’s September 2025 milestone release reported $30M+ in cumulative savings with VetSuite serving roughly one in ten U.S. companion-animal veterinarians. The May 2026 announcement now reports $60M in rebates alone and $150M in total benefits. The acceleration is what is new.

“Reaching 4,000 members is a reflection of what’s possible when independent veterinary practices are supported to succeed,” said Ben Wolin, President and CEO, Covetrus. Wolin framed program participation as a driver of both financial and clinical outcomes.

Covetrus is a publicly held animal-health technology and services company, taken private by Clayton, Dubilier & Rice and TPG Capital in a 2022 transaction. The company also announced in late 2025 that Chewy would acquire Covetrus’s SmartEquine business, a separate corporate-development thread but a useful tell about the Chewy-vet-vertical posture The Underbite has tracked elsewhere.

Why 4,000 practices and the disclosed economics change the consolidation conversation

The corporate side of vet consolidation has spent a decade building the better story. Mars (BluePearl, VCA, Banfield), JAB-backed NVA, Pathway Vet Alliance, Compassion-First, Ethos, and a deep bench of PE-backed roll-ups have steadily acquired independent companion-animal clinics, almost always with multiples that priced in continued consolidation tailwinds and continued independent-side disorganization.

VetSuite’s growth, with these specific numbers attached, is the first concrete sign that the independent half of the market is consolidating defensive infrastructure at scale.

Four thousand practices is roughly 12% of the 34,296 U.S. veterinary practices counted by the U.S. Census Bureau in 2023, and a higher share of the companion-animal-only subset. Covetrus’s own framing, per its September 2025 release, was that VetSuite already served “one in ten” companion-animal veterinarians at the $30M savings milestone. That puts VetSuite in striking range of the historical 15-20% plateau zone buying-group programs hit in adjacent human-medical verticals: DSOs, OSOs, GPOs for independent pharmacies. The question is whether vet-specific dynamics (clinic size distribution, supplier concentration, technology fragmentation) let VetSuite punch through that ceiling, or whether the same gravity applies.

The disclosed unit economics make the case more directly than market-share math does. $30,000 in average annual savings is a meaningful number for a typical 1-3 DVM clinic operating at low-to-mid single-digit EBITDA margins. A 27% bump in online pharmacy revenue per DVM is a directly comparable operating metric, and online pharmacy is the contested margin pool every consolidator and Chewy is fighting for. Together, those two figures are the strongest “stay independent” argument a buying group has made in a long time. They are the math an independent owner takes into a negotiation with a corporate acquirer.

The competitive set on the supply side is wider than it looks. Patterson Veterinary and Henry Schein Animal Health both serve independents through different programs and pricing. The Covetrus-MWI merger, announced in February and expected to close after September 2026, would further concentrate the distributor side. The new wrinkle is that Medline entered animal-health distribution at the shelter end of the market this week, the first formal cross-over from human-medical distribution into the vet channel. If Medline expands beyond shelter SKUs into general companion-animal clinic surgical packs in the next 12-18 months, VetSuite’s defensive moat narrows from a new direction while it deepens against the old one.

There is one structural caveat worth flagging. Covetrus is releasing program-aggregate numbers, not per-practice distributions. $30K in average savings is marketing-grade math. The operator-grade version is: what does a bottom-quartile member practice save versus a top-quartile? Until Covetrus shows that distribution, the aggregate number sells the program but cannot fully defend it against a sophisticated buyer comparing offers.

What the next milestone and the supplier-side response will signal

The 5,000-practice milestone and the time to get there. The pace from prior milestones is the leading indicator. If VetSuite adds the next 1,000 practices in less than 12 months, the network-effects flywheel is real. If it takes 18+, the buying-group plateau is starting to bite.

Per-practice distribution disclosure. The aggregate $30K savings number is a marketing asset. A disclosed range or distribution would be a recruiting asset for the next 1,000 practices. Watch Covetrus’s next investor-facing or AAHA-conference presentation for either.

Medline’s next animal-health SKU. If Medline expands beyond shelter packs into general companion-animal clinic surgical packs or broader medical-surgical kits, Covetrus, Patterson, and Henry Schein all face a new entrant with a substantial human-medical kitting business behind it. The supplier-side competitive map then redraws.

Corporate-acquirer response. Mars, NVA, and the PE-backed roll-ups have been the buyers in the consolidation cycle. If VetSuite’s defensive math gets compelling enough to slow seller flow, acquirers will need to raise multiples to keep deal flow, or pivot harder toward greenfield and specialty. The first signal would be a visible multiple compression in announced 2026-2027 transactions.

Source: Covetrus announcement via PR Newswire